NASDAQ:ESPR Esperion Therapeutics Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Esperion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $6.46 -0.01 (-0.15%) (As of 06/27/2022 09:45 AM ET) Add Compare Share Today's Range$6.45▼$6.5750-Day Range$4.77▼$6.5352-Week Range$3.28▼$23.75Volume2,184 shsAverage Volume1.26 million shsMarket Capitalization$407.03 millionP/E RatioN/ADividend YieldN/APrice Target$21.11 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ESPR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Esperion Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ESPR Stock Forecast (MarketRank)Overall MarketRank™1.85 out of 5 starsMedical Sector729th out of 1,411 stocksPharmaceutical Preparations Industry354th out of 672 stocksAnalyst Opinion: 3.1Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 - 3.1 Analyst's Opinion Consensus RatingEsperion Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 4 buy ratings, 2 hold ratings, and 2 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $21.11, Esperion Therapeutics has a forecasted upside of 226.3% from its current price of $6.47.Amount of Analyst CoverageEsperion Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 4.7 Community Rank Outperform VotesEsperion Therapeutics has received 579 “outperform” votes. (Add your “outperform” vote.)Underperform VotesEsperion Therapeutics has received 239 “underperform” votes. (Add your “underperform” vote.)Community SentimentEsperion Therapeutics has received 70.78% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Esperion Therapeutics and other stocks. Vote “Outperform” if you believe ESPR will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ESPR will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldEsperion Therapeutics does not currently pay a dividend.Dividend GrowthEsperion Therapeutics does not have a long track record of dividend growth. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Esperion Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $25,141.00 in company stock.Percentage Held by InsidersOnly 2.40% of the stock of Esperion Therapeutics is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Esperion Therapeutics are expected to grow in the coming year, from ($3.73) to ($2.05) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Esperion Therapeutics is -0.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Esperion Therapeutics is -0.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Esperion Therapeutics (NASDAQ:ESPR)Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.Read More ESPR Stock News HeadlinesJune 22, 2022 | americanbankingnews.comEsperion Therapeutics, Inc. (NASDAQ:ESPR) CEO Sheldon L. Koenig Sells 4,552 Shares of StockJune 20, 2022 | americanbankingnews.comBrokerages Set Esperion Therapeutics, Inc. (NASDAQ:ESPR) Target Price at $21.11June 14, 2022 | finance.yahoo.comIs Esperion Therapeutics, Inc. (NASDAQ:ESPR) Popular Amongst Institutions?June 3, 2022 | finance.yahoo.comReal World Data Analysis Reveals Nearly Half of All Adults at High Risk for ASCVD and Eligible for a Statin Were Not On Any StatinJune 2, 2022 | finance.yahoo.comEsperion Therapeutics (ESPR) Down 15.1% Since Last Earnings Report: Can It Rebound?June 2, 2022 | finance.yahoo.comEsperion to Participate in the 2022 Jefferies Global Healthcare ConferenceJune 1, 2022 | finance.yahoo.comEsperion Announces the Appointment of J. Martin Carroll to its Board of DirectorsMay 31, 2022 | finance.yahoo.comEsperion Announces Five Abstracts Accepted for Presentation at the National Lipid Association Scientific SessionsMay 26, 2022 | finance.yahoo.comEsperion (ESPR) Up More Than 12% YTD: What's Driving the Rally?May 17, 2022 | finance.yahoo.comEsperion to Participate in Upcoming H.C. Wainwright Global Investment ConferenceMay 13, 2022 | benzinga.comEsperion Therapeutics's Return On Capital Employed InsightsMay 7, 2022 | seekingalpha.comEsperion Therapeutics: 2021 Labors Paying Off In 2022May 4, 2022 | finance.yahoo.comEsperion (ESPR) Q1 Earnings Beat on Robust Demand for DrugsSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ESPR CUSIPN/A CIK1434868 Webwww.esperion.com Phone(734) 887-3903FaxN/AEmployees218Year FoundedN/ACompany Calendar Last Earnings5/03/2022Today6/27/2022Next Earnings (Estimated)8/02/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$21.11 High Stock Price Forecast$90.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+226.8%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($6.99) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-269.11 million Net Margins-263.04% Pretax Margin-263.04% Return on EquityN/A Return on Assets-76.38% Debt Debt-to-Equity RatioN/A Current Ratio3.68 Quick Ratio3.23 Sales & Book Value Annual Sales$78.45 million Price / Sales5.19 Cash FlowN/A Price / Cash FlowN/A Book Value($3.23) per share Price / Book-2.00Miscellaneous Outstanding Shares63,007,000Free Float61,495,000Market Cap$407.03 million OptionableOptionable Beta0.43 Esperion Therapeutics Frequently Asked Questions Should I buy or sell Esperion Therapeutics stock right now? 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Esperion Therapeutics in the last twelve months. There are currently 2 sell ratings, 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Esperion Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ESPR, but not buy additional shares or sell existing shares. View analyst ratings for Esperion Therapeutics or view top-rated stocks. What is Esperion Therapeutics' stock price forecast for 2022? 8 equities research analysts have issued twelve-month price targets for Esperion Therapeutics' shares. Their ESPR stock forecasts range from $5.00 to $90.00. On average, they expect Esperion Therapeutics' stock price to reach $21.11 in the next year. This suggests a possible upside of 226.8% from the stock's current price. View analysts' price targets for Esperion Therapeutics or view top-rated stocks among Wall Street analysts. How has Esperion Therapeutics' stock price performed in 2022? Esperion Therapeutics' stock was trading at $5.00 at the beginning of the year. Since then, ESPR shares have increased by 29.2% and is now trading at $6.46. View the best growth stocks for 2022 here. When is Esperion Therapeutics' next earnings date? Esperion Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022. View our earnings forecast for Esperion Therapeutics. How were Esperion Therapeutics' earnings last quarter? Esperion Therapeutics, Inc. (NASDAQ:ESPR) posted its quarterly earnings results on Tuesday, May, 3rd. The biopharmaceutical company reported ($0.93) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.96) by $0.03. The biopharmaceutical company earned $18.84 million during the quarter, compared to the consensus estimate of $15.41 million. Esperion Therapeutics's revenue was up 136.1% compared to the same quarter last year. During the same period in the previous year, the company earned ($3.50) EPS. View Esperion Therapeutics' earnings history. Who are Esperion Therapeutics' key executives? Esperion Therapeutics' management team includes the following people: Mr. Sheldon L. Koenig, Pres, CEO & Director (Age 56, Pay $728.91k)Dr. Joanne Micale Foody FACC, M.D., Chief Medical Officer (Age 57, Pay $471.86k)Dr. Kenneth J. Fiorelli, Chief Technical Operations OfficerMr. Benjamin Church, Head of Corp. Communications & Investor RelationsMr. Benjamin O. Looker, Gen. Counsel & Corp. Sec. (Age 40)Mr. Keith F. Lenden, VP of Corp. Devel. & Strategy (Age 49)Ms. Betty Jean Swartz, Chief Strategy OfficerMr. Eric J. Warren R.Ph., Chief Commercial Officer (Age 49)Ms. April Seiler, Sr. Director of Project ManagementRoberta Peterson, Sr. Director of National Accounts What is Tim Mayleben's approval rating as Esperion Therapeutics' CEO? 20 employees have rated Esperion Therapeutics CEO Tim Mayleben on Glassdoor.com. Tim Mayleben has an approval rating of 80% among Esperion Therapeutics' employees. Who are some of Esperion Therapeutics' key competitors? Some companies that are related to Esperion Therapeutics include Lyell Immunopharma (LYEL), Amphastar Pharmaceuticals (AMPH), Xencor (XNCR), Aurinia Pharmaceuticals (AUPH), Travere Therapeutics (TVTX), Dynavax Technologies (DVAX), Supernus Pharmaceuticals (SUPN), Ligand Pharmaceuticals (LGND), Cryoport (CYRX), Taro Pharmaceutical Industries (TARO), Madrigal Pharmaceuticals (MDGL), Sierra Oncology (SRRA), Day One Biopharmaceuticals (DAWN), BridgeBio Pharma (BBIO) and Axsome Therapeutics (AXSM). View all of ESPR's competitors. What other stocks do shareholders of Esperion Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Esperion Therapeutics investors own include ALDW (ALDW), Targa Resources (TRGP), Navios Maritime Partners (NMM), NVIDIA (nvda), Micron Technology (MU), SFL (SFL), Gilead Sciences (GILD), Boeing (BA), Alibaba Group (BABA) and BioMarin Pharmaceutical (bmrn). What is Esperion Therapeutics' stock symbol? Esperion Therapeutics trades on the NASDAQ under the ticker symbol "ESPR." Who are Esperion Therapeutics' major shareholders? Esperion Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Wasatch Advisors Inc. (12.93%), Deep Track Capital LP (9.52%), Vanguard Group Inc. (7.13%), Bellevue Group AG (6.82%), Paradigm Biocapital Advisors LP (1.84%) and Rhenman & Partners Asset Management AB (1.56%). Company insiders that own Esperion Therapeutics stock include Eric Warren, Sheldon L Koenig, Target N V Biotech and Timothy M Mayleben. View institutional ownership trends for Esperion Therapeutics. Which major investors are selling Esperion Therapeutics stock? ESPR stock was sold by a variety of institutional investors in the last quarter, including Bellevue Group AG, Walleye Trading LLC, State Street Corp, Monaco Asset Management SAM, PDT Partners LLC, UBS Group AG, Group One Trading L.P., and Bank of America Corp DE. Company insiders that have sold Esperion Therapeutics company stock in the last two years include Eric Warren, and Sheldon L Koenig. View insider buying and selling activity for Esperion Therapeutics or view top insider-selling stocks. Which major investors are buying Esperion Therapeutics stock? ESPR stock was purchased by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., Vanguard Group Inc., Renaissance Technologies LLC, Deep Track Capital LP, Paradigm Biocapital Advisors LP, Northern Trust Corp, Bank of New York Mellon Corp, and Goldman Sachs Group Inc.. View insider buying and selling activity for Esperion Therapeutics or or view top insider-buying stocks. How do I buy shares of Esperion Therapeutics? Shares of ESPR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Esperion Therapeutics' stock price today? One share of ESPR stock can currently be purchased for approximately $6.46. How much money does Esperion Therapeutics make? Esperion Therapeutics (NASDAQ:ESPR) has a market capitalization of $407.03 million and generates $78.45 million in revenue each year. The biopharmaceutical company earns $-269.11 million in net income (profit) each year or ($6.99) on an earnings per share basis. How many employees does Esperion Therapeutics have? Esperion Therapeutics employs 218 workers across the globe. How can I contact Esperion Therapeutics? Esperion Therapeutics' mailing address is 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI, 48108. The official website for Esperion Therapeutics is www.esperion.com. The biopharmaceutical company can be reached via phone at (734) 887-3903 or via email at [email protected]. This page (NASDAQ:ESPR) was last updated on 6/27/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here